No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products. This portfolio includes various over-the-counter (OTC) remedies addressing common ailments such as coughs and colds, eye care, liver conditions, mineral deficiencies, vitamin supplementation, circulatory health, and general wellness tonics. Complementing these are its prescription-only (ETC) medicines, which encompass treatments for a broad spectrum of medical needs, including diabetes, cardiovascular disorders, metabolic imbalances, digestive issues, immune system modulation, obesity, genitourinary and anal conditions, neurological and psychiatric disorders, pain and inflammation, infections, and anti-cancer therapies. Beyond pharmaceuticals, Kwang Dong offers health supplements and a diverse selection of beverages, ranging from general consumer drinks to functional and traditional health-focused options. The company also extends its operations to include the management of hospitals and facilitates widespread product distribution through various retail and wholesale channels, including discount stores, television home shopping, and online e-commerce platforms. Furthermore, Kwang Dong Pharmaceutical acts as a comprehensive MRO (Maintenance, Repair, and Operations) service provider, specializing in the procurement of raw materials, intermediate goods, and industrial consumables, with services extending to construction and international sourcing.
www.ekdp.comNo one on the platform currently holds 009290.KS.
No tracked institution reports a position in 009290.KS as of their last filing.
No one on the platform has traded 009290.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.6% | 4.4% | 5.2% | — | — | — |
| Rev. Growth % | 1.1% | 5.9% | ||||
| Profit Margin % | 1.3% | 1.9% | 2.2% | |||
| Free Cash Flow Margin % | 3.4% | -0.1% | 0.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.15T | — | $534.00 | $534.00–$534.00 | — | 1 |
| 2027 | $1.17T | +2.2% | $527.00 | $527.00–$527.00 | — | 1 |
| 2028 | $1.25T | +6.5% | $606.00 | $606.00–$606.00 | — | 1 |
| 2029 | $1.32T | +5.5% | $675.00 | $675.00–$675.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 009290.KSKwang Dong Pharmaceutical Co., Ltd. | $6370.00 | -0.16% | $316.3B | — |
| 000520.KSSamil Pharmaceutical Co.,Ltd | $7010.00 | -0.57% | $149.8B | — |
| 001630.KSChong Kun Dang Holdings Corp. | $38550.00 | -0.77% | $183.5B | — |
| 005500.KSSamjin Pharmaceuticals Co., Ltd. | $18390.00 | -0.86% | $232.8B | — |
| 007570.KSIlyang Pharmaceutical Co.,Ltd | $7910.00 | -0.88% | $141.8B | — |
| 096760.KSJW Holdings Corporation | $4280.00 |
Source: Financial Modeling Prep · peers by sector/industry
| +0.23% |
| $296.1B |
| — |
| 102460.KSREYON Pharmaceutical Co., Ltd. | $9960.00 | -0.60% | $182.7B | — |